Provided by Tiger Trade Technology Pte. Ltd.

Turn Therapeutics (Direct Listing)

14.94
+1.128.10%
Post-market: 14.940.00000.00%19:44 EDT
Volume:929.96K
Turnover:14.05M
Market Cap:445.03M
PE:-51.16
High:16.45
Open:13.80
Low:13.80
Close:13.82
52wk High:26.50
52wk Low:2.57
Shares:29.79M
Float Shares:11.41M
Volume Ratio:6.62
T/O Rate:8.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2921
EPS(LYR):-0.1152
ROE:-686.28%
ROA:-50.27%
PB:647.90
PE(LYR):-129.64

Loading ...

Agri R&D innovations move from lab to market in Hubei

同花顺
·
Sep 17

Analysts Offer Insights on NA Companies: Beta Bionics, Inc. (BBNX), Meta Platforms (META) and Turn Therapeutics Inc (TTRX)

TIPRANKS
·
Sep 15

Turn Therapeutics Inc (TTRX) was downgraded to a Sell Rating at WBB Securities

TIPRANKS
·
Sep 14

Turn Therapeutics to Present at Stifel Virtual Immunology and Inflammation Forum

Reuters
·
Sep 10

Turn Therapeutics Names Former CDC Director Robert Redfield Chief Scientific Officer

Reuters
·
Sep 09

Turn Therapeutics Appoints Former Cdc Director Robert R. Redfield, M.d., as Chief Scientific Officer

THOMSON REUTERS
·
Sep 09

Novabridge Appoints Martin Dewhurst to Board of Directors as an Independent Director

THOMSON REUTERS
·
Sep 08

Turn Therapeutics Says Mouse Study Shows GX-03 Cuts Dermatitis Severity 66%

Reuters
·
Aug 20

Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance

TIPRANKS
·
Aug 18

Turn Therapeutics Raises $1.35M Through Private Placement

TIPRANKS
·
Aug 18

Turn Therapeutics Sells 135,000 Shares in Private Placement for $1.35 Million

Reuters
·
Aug 18

Ladenburg Thalmann & Co. Keeps Their Buy Rating on Turn Therapeutics Inc (TTRX)

TIPRANKS
·
Aug 14

Turn Therapeutics Q2 Net Loss Per Share Widens on Higher R&D Costs

Reuters
·
Aug 13

Turn Therapeutics Q2 FY26 Net Loss Widens to USD 5.85 Million

Reuters
·
Aug 13

Turn Therapeutics Q2 EPS USD -0.2

THOMSON REUTERS
·
Aug 13

Press Release: Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 13

Turn Therapeutics Releases Corporate Deck Outlining GX-03 Topical Immunomodulator Program for Atopic Dermatitis

Reuters
·
Jul 28

Turn Therapeutics CEO to Ring NASDAQ Closing Bell

Reuters
·
Jul 28

Turn Therapeutics Shares Rise on Expanded Phase 2 Study for Eczema Treatment

Dow Jones
·
Jul 21

Turn Therapeutics - Gx-3 Shows Clinically Meaningful Efficacy in Patients with Easi Scores 1.1 to 7

THOMSON REUTERS
·
Jul 07